Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAK 243

Next Previous
Drug Profile

TAK 243

Alternative Names: AOB-87172; MLN-7243; TAK-243

Latest Information Update: 01 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium
  • Developer Takeda Oncology
  • Class Antineoplastics; Cyclopentanes; Organic sulfur compounds; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action NF-kappa B inhibitors; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Lymphoma

Most Recent Events

  • 25 Jan 2024 National Cancer Institute plans a phase I trial for Solid tumours and Lymphoma (Late-stage disease, Metastatic-disease, Second-line therapy or greater) (IV) in April 2024 (NCT06223542)
  • 14 Apr 2023 Preclinical trials in Lymphoma in USA (Intratumoural)
  • 14 Apr 2023 Pharmacodynamics data from a preclinical studies in Lymphoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top